From: Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer
Characteristics | Value (%) |
---|---|
Median age, years (range) | 57 (30-84) |
Gender | Â |
   Male | 40 (59.7) |
   Female | 27 (40.3) |
Stage at initial diagnosis | Â |
   ypStage 0 | 3 (4.2) |
   pStage I/ypStage I | 5 (7.0)/1 (1.4) |
   pStage II/ypStage II | 14 (19.7)/3 (4.2) |
   pStage III/ypStage III | 21 (29.6)/8 (11.3) |
   pStage IV/ypStage IV | 6 (8.5)/1 (1.4) |
   pT1-2Nx | 5 (7.0) |
Recurrence history | Â |
   0 | 51 (76.1) |
   1 | 16 (23.9) |
Symptoms at recurrence | Â |
   Yes | 20 (29.9) |
   No | 47 (70.1) |
Recurrent site | Â |
   Central | 21 (31.3) |
   Lateral | 30 (44.8) |
   Posterior | 16 (23.9) |
Pretreatment CEA | Â |
   Normal (≤ 5 ng/mL) | 37 (55.2) |
   High (> 5 ng/mL) | 30 (44.8) |
Salvage treatment | Â |
   Surgery + CRT | 45 (67.2) |
   CRT alone | 22 (32.8) |
Chemotherapy regimen | Â |
   Fluoropyrimidine-alone | 35 (52.2) |
   Irinotecan or Oxaliplatin-based | 31 (46.3) |
   No | 1 (1.5) |
Radicality of resection | Â |
   R0 | 19 (28.4) |
   R1 | 24 (35.8) |
   R2 | 2 (4.0) |
   No surgery | 22 (32.8) |
Median radiation dose, Gy (range) | 57.2 (44.3-74.4) |